ライフサイエンスコーパス: erythropoietin

1 ex difference in mouse metabolic response to erythropoietin.

2 ed basal expression and hypoxic induction of erythropoietin.

3 tely quantify relative sialylation levels of Erythropoietin.

4 throblasts through a mechanism distinct from erythropoietin.

5 nd an indirect relation that was mediated by erythropoietin.

6 ally significant dimension to the biology of erythropoietin.

7 tion, often caused by impaired production of erythropoietin.

8 er injection, a time course similar to serum erythropoietin.

9 is produced by erythroblasts in response to erythropoietin.

10 erythroid progenitors are hypersensitive to erythropoietin.

11 d with 1 of 392 patients who did not receive erythropoietin.

12 ose-dependent manner in animals treated with erythropoietin.

13 response to hypoxia, including production of erythropoietin.

14 pted in 9 patients due to anemia; 4 received erythropoietin.

15 s to demonstrate the functional existence of erythropoietin.

16 ndomly assigned to receive recombinant human erythropoietin (3000 IU/kg; n=256) or placebo (n=239) in

17 Intravenous erythropoietin (500 IU/kg per dose) or saline.

18 her a saline solution or a recombinant human erythropoietin (5000 IU/kg).

19 as determined by suppression of circulating erythropoietin, a HIF-2 target and possible pharmacodyna

20 et gene characterized was EPO, which encodes erythropoietin-a glycoprotein hormone that controls eryt

21 Here, we show that erythropoietin activates AKT, which phosphorylates GATA-

22 on of granulocyte colony-stimulating factor, erythropoietin, aminocaproic acid, and phytonadione was

23 (High Dose of Erythropoietin Analogue After Cardiac Arrest [Epo-ACR-02

24 A nonhematopoietic erythropoietin analogue, ARA 290, has similar properties

25 Safety concerns with erythropoietin analogues and intravenous (IV) iron for t

26 he EPOR dimer in the presence and absence of erythropoietin and a series of agonistic or antagonistic

27 Increases in erythropoietin and angiogenic signaling following anti-V

28 n of this stress response was independent of erythropoietin and BMP4, and was observed in endothelial

29 hropoiesis-stimulating agents (ESAs) such as erythropoietin and darbepoetin in preterm and term infan

30 Moreover, erythropoietin and erythroferrone target Smad1/5 signali

31 mpensatory erythropoiesis via the regulators erythropoietin and erythroferrone.

32 Serum erythropoietin and growth differentiation factor 15 (GDF

33 sion, hemoglobin and hepcidin increased, and erythropoietin and growth differentiation factor-15 decr

34 CD105-LV resulted in substantially increased erythropoietin and hematocrit levels.

35 There was no interaction between erythropoietin and hemoglobin transfusion threshold.

36 SnPP administration led to a decrease in erythropoietin and increase in hepcidin serum levels, ch

37 ne, amlodipine, carvedilol, cholecalciferol, erythropoietin, and a phosphate binder.

38 CD133(-) cells did not synthesize erythropoietin, and CD133(+) progenitor cells stopped pr

39 Combinatorial use of zebrafish Tpo, erythropoietin, and granulocyte colony stimulating facto

40 Higher levels of endogenous erythropoietin are associated with incident HF in older

41 (1:1) between no treatment (control arm) or erythropoietin at 500 U/kg per week (EPO arm).

42 ternal 25(OH)D was inversely associated with erythropoietin at both midgestation (P <0.05) and delive

43 Priming with erythropoietin before cell transplantation is an efficie

44 for its possible role as indirect marker of erythropoietin blood doping.

45 Seventy percent of patients required erythropoietin, blood transfusions, or RBV dose reductio

46 include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell sur

47 tor (MPL) but not of Ba/F3-human receptor of erythropoietin cells.

48 Carbamylated erythropoietin (CEPO) lacks both erythropoietic and vaso

49 Erythropoietin, commonly known as EPO, is a glycoprotein

50 e reported in 9 of 295 patients who received erythropoietin, compared with 1 of 392 patients who did

51 Among them, macrophages are emerging as erythropoietin-complementary regulators of erythroid dev

52 ood cell units per 8 weeks); pre-study serum erythropoietin concentration (<200 IU/L, 200-500 IU/L, a

53 Erythropoietin concentration was measured in 2488 partic

54 ly lower than those in the recombinant human erythropoietin control arm in the hemodialysis study, an

55 Erythropoietin controls the proliferation and survival o

56 CT to evaluate whether priming of ECFCs with erythropoietin could enhance their homing to the ischemi

57 genitors delays G1-S progression and arrests erythropoietin-dependent cell growth while favoring term

58 d decreased inflammation, independent of the erythropoietin dosage.

59 An abrupt decline in erythropoietin dosing and hemoglobin concentration began

60 This response impairs erythropoietin-driven erythropoiesis and underlies eryth

61 Erythropoietin during pregnancy was significantly negati

62 ession in mice constitutively overexpressing erythropoietin (Epo) (Tg6 mice), which leads to excessiv

63 Recombinant erythropoietin (EPO) analogs [erythropoiesis-stimulating

64 c arrest (OHCA) patients with a high dose of erythropoietin (Epo) analogs.

65 Clinical and animal studies implicate erythropoietin (EPO) and EPO receptor (EPOR) signaling i

66 essential mediators of red cell production, erythropoietin (EPO) and its cell surface receptor (EPO

67 Erythropoietin (EPO) and its cell surface receptor (EPOR

68 dimeric receptor-ligand system, the cytokine Erythropoietin (EPO) and its receptor (EpoR), to dimeriz

69 Erythropoietin (EPO) and its receptor are expressed in a

70 Erythropoietin (EPO) and its receptor are highly express

71 process relies predominantly on the hormone erythropoietin (EPO) and its transcription factor hypoxi

72 Erythropoietin (Epo) binding to the Epo receptor (EpoR)

73 to estimate time trends in hemoglobin (Hgb), erythropoietin (EPO) dose, intravenous (IV) iron dose, f

74 AFPL-Luc was constructed by insertion of the erythropoietin (Epo) enhancer for hypoxic cancer specifi

75 hd2, and Phd3 (Phd(1/2/3)hKO) promoted liver erythropoietin (EPO) expression 1246-fold, whereas renal

76 ascular endothelial growth factor (VEGF) and erythropoietin (EPO) expression were increased during hy

77 ones involved in erythropoiesis, such as the ERYTHROPOIETIN (EPO) gene.

78 Recent studies have demonstrated that erythropoietin (EPO) has extensive nonhematopoietic biol

79 Erythropoietin (EPO) has neurotrophic actions and aids n

80 Erythropoietin (EPO) has shown beneficial effects in the

81 We found that expression of erythropoietin (EPO) in a HEK293S N-acetylglucosaminyltr

82 tor (EPOR) mediate the cellular responses to erythropoietin (EPO) in different tissues.

83 Erythropoietin (EPO) increases neuroplasticity and reduc

84 Blood erythropoietin (EPO) increases primarily to hypoxia.

85 ting the LPA 3 receptor subtype (LPA3) under erythropoietin (EPO) induction.

86 Erythropoietin (EPO) is a hormone that induces red blood

87 Correction of anemia with erythropoietin (EPO) is associated with improved kidney

88 Erythropoietin (EPO) is one of the main therapeutics use

89 Erythropoietin (Epo) is produced in the kidney and liver

90 Erythropoietin (EPO) is the cytokine that regulates red

91 Erythropoietin (EPO) is the primary regulator of red blo

92 Elevated endogenous plasma erythropoietin (EPO) levels have been associated with pr

93 asts number, reduces apoptosis, and enhances erythropoietin (Epo) levels in controls, but not in Tfr2

94 ction induced anemia, splenomegaly, elevated erythropoietin (EPO) levels, and extramedullary erythrop

95 Erythropoietin (EPO) may be a beneficial tissue-protecti

96 nced polycythemia because of increased renal erythropoietin (Epo) production.

97 Ligation of erythropoietin (EPO) receptor (EPOR) JAK2 kinase complex

98 nally, all S-HB had increased phosphorylated erythropoietin (EPO) receptor and phosphorylated STAT-5

99 exaggerated erythropoiesis due to augmented erythropoietin (EPO) sensitivity.

100 fish, murine, and human models, we show that erythropoietin (EPO) signaling, together with the GATA1

101 Erythropoietin (EPO) stimulates proliferation of early-s

102 The erythroid stress cytokine erythropoietin (Epo) supports the development of committ

103 sly reported that the topical application of erythropoietin (EPO) to cutaneous wounds in rats and mic

104 when erythropoiesis is acutely stimulated by erythropoietin (EPO) to favor iron supply to maturing er

105 d differentiation of CD34(+) cells following erythropoietin (EPO) treatment.

106 Low serum erythropoietin (EPO) values were specific for PV, but no

107 nd mRNA of liver and kidney VEGF, IGF-1, and erythropoietin (EPO) were determined.

108 ia-inducible factor 1-alpha (HIF-1alpha) and erythropoietin (EPO) were measured as potential mechanis

109 Erythropoietin (EPO), a glycoprotein hormone indispensab

110 Erythropoietin (EPO), a humoral regulator of erythropoie

111 in erythropoiesis and is the main source of erythropoietin (EPO), an oxygen-sensitive glycoprotein t

112 ond-Blackfan anaemia, are not treatable with erythropoietin (Epo), because the colony-forming unit er

113 The total synthesis of a homogeneous erythropoietin (EPO), possessing the native amino acid s

114 ied this approach in vivo to the anemia drug erythropoietin (EPO), to direct its activity to EPO rece

115 The hormone erythropoietin (EPO), which is synthesized in the kidney

116 reached the kidney and reduced expression of erythropoietin (Epo), which we identified as a MIR122 ta

117 CKD progresses with fibrosis and erythropoietin (Epo)-dependent anemia, leading to increa

118 ter colony-forming unit erythroid progenitor erythropoietin (Epo)-dependent progenitors.

119 We provide evidence that blocking erythropoietin (EPO)-EPO receptor (R) signaling promotes

120 ated that low reticulocytosis and suppressed erythropoietin (Epo)-induced erythropoiesis are features

121 Alternate erythropoietin (EPO)-mediated signaling via the heterome

122 Lyn is involved in erythropoietin (Epo)-receptor signaling and erythroid ho

123 inducible factor (HIF)-mediated induction of erythropoietin (EPO).

124 to activate target genes, including that for erythropoietin (EPO).

125 on of HIF2alpha, which induces expression of erythropoietin (Epo).

126 homozygous mutation (R150Q) in the cytokine erythropoietin (EPO).

127 erythroblasts in response to stimulation by erythropoietin (EPO).

128 o be related to impaired production of renal erythropoietin (Epo).

129 ythropoiesis, as they are the main source of erythropoietin (EPO).

130 and his parents revealed hypersensitivity to erythropoietin (EPO).

131 ive of the stress-induced (hemolytic or post-erythropoietin [Epo]) treatment, only native CD11b(lo) s

132 Erythropoietin exerts anti-inflammatory, antiapoptotic,

133 red; this was accompanied by increased renal erythropoietin expression and stabilization of hypoxia-i

134 derlying mechanism is suppression of hepatic erythropoietin expression associated with the downregula

135 Suppression of hepatic erythropoietin expression by nitrate may thus act to dec

136 G cells, angiotensin II negatively regulated erythropoietin expression in the transformed cells.

137 Erythropoietin expression was strongly enhanced.

138 s of the kidney suppresses renin and induces erythropoietin expression, this study aimed to character

139 um bilirubin, reticulocyte counts, and serum erythropoietin following intestinal HIF-2alpha disruptio

140 lysis study; continuing on recombinant human erythropoietin for the hemodialysis study) for 4 weeks,

141 revention of contrast-induced AKI and use of erythropoietin for the prevention of AKI, two therapeuti

142 We hypothesized that the plasmid human erythropoietin gene (phEPO) delivered by our bioreducibl

143 Delivery of the erythropoietin gene with mCD105-LV resulted in substanti

144 g cells of Vhl (-/-(REN)) mice expressed the erythropoietin gene, and they were markedly polycythemic

145 k-in mutation results in upregulation of the erythropoietin gene, erythrocytosis, and augmented hypox

146 This homogeneous erythropoietin glycosylated at the three wild-type aspar

147 34/89 [38.2%; 95% CI, 28.1% to 49.1%]), both erythropoietin groups were futile (first dosing regimen:

148 Women with erythropoietin >75th percentile during pregnancy exhibit

149 fewer infants treated with recombinant human erythropoietin had abnormal scores for white matter inju

150 As administrated clinically, erythropoietin has a polypeptide backbone with complex d

151 eated with stable doses of recombinant human erythropoietin (hemodialysis study).

152 Human erythropoietin (hEPO) is an erythropoiesis stimulating h

153 Human erythropoietin (hEPO) or granulocyte colony-stimulating

154 DNA methyltransferases and erythropoietin hypermethylation are upregulated in myofi

155 irin dose in 29% of the patients, the use of erythropoietin in 54%, and blood transfusions in 12%.

156 t, we have recently shown that expression of erythropoietin in a GnTI knock-out, FUT8-overexpressing

157 reased vector-mediated hepatic expression of erythropoietin in C57BL/6 mice.

158 phenotype thought responsible for producing erythropoietin in humans remains unclear.

159 ns between vitamin D status, hemoglobin, and erythropoietin in maternal serum.

160 1 induced hypermethylation and repression of erythropoietin in pericytes; these effects were prevente

161 e, but these cells do not produce sufficient erythropoietin in response to hypoxic stimuli.

162 ntiation pathway of humans, and implicate an erythropoietin-independent, macrophage-associated pathwa

163 lts identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further pro

164 light perception (NLP) despite prescribed IV erythropoietin injections 20,000 units daily for 3 days

165 ignaling, while preventing responsiveness to erythropoietin-instigated signals that promote different

166 omatin and abrogates hepcidin suppression by erythropoietin, iron deficiency, thalassemia, and hemoch

167 fold greater risk of anemia, suggesting that erythropoietin is a sensitive predictor of anemia at del

168 Erythropoietin is a signaling glycoprotein that controls

169 patients with heart failure (HF), high serum erythropoietin is associated with risk of recurrent HF a

170 gulation of the haematopoietic growth factor erythropoietin led to the unexpected discovery of a wide

171 date the mechanisms through which endogenous erythropoietin levels associate with specific outcomes.

172 o-Stat5, most likely because of the elevated erythropoietin levels in response to the HU-induced anem

173 have evaluated the association of endogenous erythropoietin levels with clinical outcomes in the comm

174 pported by evidence that i) mRNA and protein erythropoietin levels within liver and serum increased i

175 These animals also exhibited lower erythropoietin levels, a significant amelioration of ine

176 Our data show that plasma erythropoietin levels, erythrocyte maturation markers, e

177 nomegaly, and bone pathology, while reducing erythropoietin levels, improving erythrocyte morphology,

178 than in controls, irrespective of comparable erythropoietin levels.

179 ne cytomegalovirus infection decreased serum erythropoietin levels.

180 ed normal age but were anemic because of low erythropoietin levels.

181 s unexpected for a JAK1/2 inhibitor, because erythropoietin-mediated JAK2 signaling is essential for

182 The emergence of novel and innovative erythropoietin-mimetic agents (EMAs) has been continuous

183 hCMV inhibited hypoxia-induced expression of erythropoietin mRNA and protein.

184 Randomized clinical trial of 200 patients (erythropoietin, n = 102; placebo, n = 98) with closed he

185 a nonrandomized subset of 165 infants (n=77 erythropoietin; n=88 placebo), brain abnormalities were

186 Five patients (15%) required erythropoietin; no patient required blood transfusion.

187 dialysis and not receiving recombinant human erythropoietin (nondialysis study) and in patients with

188 d head injury, neither the administration of erythropoietin nor maintaining hemoglobin concentration

189 ng anti-VEGF, reduced p-STAT3 and increased erythropoietin occurred at p18.

190 estigate: 1) the effect of recombinant human erythropoietin on brain edema using diffusion-weighted m

191 oputamen; 2) the effect of recombinant human erythropoietin on brain tissue PO(2) in similar experime

192 local cooling with water and intraperitoneal erythropoietin once a day for five days starting 45 minu

193 e is limited information about the effect of erythropoietin or a high hemoglobin transfusion threshol

194 Erythropoietin or placebo was initially dosed daily for

195 Erythropoietin or VEGF stimulated hRMVEC proliferation a

196 Under hypoxia, erythropoietin peaked at MG2 (P < 0.001) paralleled by i

197 -stained percent IVNV and AVA; VEGF protein, erythropoietin, phosphorylated extracellular signal-rela

198 sumed cardiac cause, early administration of erythropoietin plus standard therapy did not confer a be

199 10), PBS-primed ECFCs (ECFCPBS, n = 13), or erythropoietin-primed ECFCs (ECFCEPO, n = 10).

200 stored with ECFCs and almost totally so with erythropoietin priming (control, 72% +/- 2%; ECFCPBS, 90

201 lighted its notable role in ECFC homing with erythropoietin priming (ECFCEPO, 147% +/- 14%, n = 4; EC

202 Erythropoietin priming increased homing of ECFCs to the

203 We previously reported that erythropoietin priming of ECFCs increased their in vitro

204 Renal erythropoietin-producing cells (REPCs) remain in the kid

205 into fibroblast-like cells resembling native erythropoietin-producing cells located in the tubulointe

206 In human erythropoietin-producing cells, hCMV inhibited hypoxia-i

207 tudy aims to investigate the significance of erythropoietin-producing hepatocellular (Eph)A2 expressi

208 like kinase suppressor of Ras 1 (KSR1), EPH (erythropoietin-producing hepatocellular carcinoma) recep

209 Here, we found that erythropoietin-producing hepatocellular receptor A4 (Eph

210 Several erythropoietin-producing hepatocellular receptor B famil

211 Beyond the well-defined role of the Eph (erythropoietin-producing hepatocellular) receptor tyrosi

212 Previous analysis on the thymus of erythropoietin-producing hepatocyte kinases (Eph) B knoc

213 The erythropoietin-producing hepatoma A2 receptor (EphA2) is

214 Trans interactions of erythropoietin-producing human hepatocellular (Eph) rece

215 Erythropoietin-producing human hepatocellular carcinoma

216 nontoxic doses of 5-azacytidine can restore erythropoietin production and ameliorate anemia in the s

217 age-related changes, organ function such as erythropoietin production in the kidney may become subop

218 Treatment with HIF stabilizers rescues erythropoietin production in these cells, but the mechan

219 by erythrocytosis with suppressed endogenous erythropoietin production, bone marrow panmyelosis, and

220 ts, but it is not known whether hCMV effects erythropoietin production.

221 nts with acute-on-chronic liver failure, and erythropoietin promoted hepatic regeneration in animal s

222 te protein/peptide context, such as with the erythropoietin protein, a V3 polypeptide derived from HI

223 Injection of a transposon expressing erythropoietin raised the haematocrit, indicating that t

224 To analyze HIF and erythropoietin, rats at P5 were injected with DMOG (200

225 failing signal transduction at the homomeric erythropoietin receptor (EpoR) and at the heteromeric in

226 rythropoiesis, we investigated its action on erythropoietin receptor (EpoR) cellular dynamics.

227 Erythropoietin receptor (EpoR) dimerization is an import

228 L traptamers) that specifically activate the erythropoietin receptor (EPOR) in mouse cells to confer

229 Here, we show that erythropoietin receptor (EPOR) is hydroxylated on prolin

230 Two distinct forms of the erythropoietin receptor (EPOR) mediate the cellular resp

231 und and unbound forms, the activation of the erythropoietin receptor (EPOR) was initially proposed to

232 d property of all EMAs, to bind on the human erythropoietin receptor (hEPOR), is therefore exploited.

233 escribe four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromo

234 regulation in the liver and associates with erythropoietin receptor in erythroid cells.

235 cal and suggests that studying modulation of erythropoietin receptor pathway may lead to strategies i

236 n receptor subunits, sucrase-isomaltase, the erythropoietin receptor, and two of the subunits of the

237 vates the 3 main myeloid cytokine receptors (erythropoietin receptor, granulocyte colony-stimulating

238 tions between transferrin receptor-2 and the erythropoietin receptor.

239 ge-restricted genes, including Klf1/Eklf and Erythropoietin receptor.

240 f prolyl hydroxylase significantly increased erythropoietin release by CD133(+) progenitors.

241 In mammals, hypoxia-triggered erythropoietin release increases red blood cell mass to

242 Erythropoietin represents an easy-to-use therapeutic app

243 light on the molecular mechanisms underlying erythropoietin repression in kidney myofibroblasts and d

244 Serum erythropoietin responses to hypoxia also differed betwee

245 lity and hospitalization rates and decreased erythropoietin responsiveness.

246 for the glycoprofiling of recombinant human erythropoietin, revealing 74 glycoforms in a 60-min run.

247 Treatment with recombinant human erythropoietin reversed all of these traumatic brain inj

248 While recombinant human erythropoietin (rhEpo) has been widely used to treat ane

249 ncrease the sialylation of recombinant human erythropoietin (rhEPO) produced in CHO cells.

250 emoglobin (Hb) response to recombinant human erythropoietin (rhEPO) therapy after hematopoietic cell

251 onal antibodies (mAbs) and recombinant human erythropoietin (rhEPO).

252 illegal administration of recombinant human erythropoietin (rHuEPO) among athletes is largely prefer

253 ore complex N-glycans from recombinant human erythropoietin (rHuEPO) expressed in Chinese hamster ova

254 ardioprotective effects of recombinant human erythropoietin (rHuEPO) protein in animal experiments ha

255 pe of juxtaglomerular cells from a renin- to erythropoietin-secreting cell type, presumably in respon

256 errin receptor (sTfR), hepcidin, serum iron, erythropoietin, serum folate, vitamin B-12, C-reactive p

257 These observations suggest that the altered erythropoietin signaling is focal and suggests that stud

258 find-me" signals from apoptotic cells induce erythropoietin signaling within macrophages to prime the

259 to S-HB conversion may be associated with an erythropoietin-signaling loop.

260 lation fingerprinting by comparing different Erythropoietin sources without the need for any sample p

261 We previously demonstrated that erythropoietin-stimulated clone-1, which is selectively

262 6.88 mg/wk active control; P<0.001) and less erythropoietin-stimulating agent (median epoetin-equival

263 sferrin saturation, and intravenous iron and erythropoietin-stimulating agent usage as prespecified s

264 iron stores and reduces intravenous iron and erythropoietin-stimulating agent use while maintaining h

265 The efficacy of erythropoietin-stimulating agents (ESAs) for improving h

266 Administration boxed warning was issued for erythropoietin-stimulating agents (ESAs) regarding serio

267 Trials of erythropoietin-stimulating agents in persons with kidney

268 gulated EPOR expression, hypersensitivity to erythropoietin stimulation, and heightened JAK-STAT acti

269 Finally, blockade of HIF-2alpha impaired erythropoietin synthesis by CD133(+) progenitors.

270 hronic hypoxemia, hypercapnia, and increased erythropoietin synthesis.

271 ll count, and lower platelet count and serum erythropoietin than those with CALR mutation.

272 This effect was independent of erythropoietin, the expression of which was increased in

273 ged by ribavirin dosage reduction (71.5%) vs erythropoietin therapy (70.9%), regardless of the timing

274 d by ribavirin dosage reduction (n = 249) or erythropoietin therapy (n = 251).

275 en managed by reducing ribavirin dose and/or erythropoietin therapy.

276 osporine, abciximab, clopidogrel, tirofiban, erythropoietin, thrombus aspiration, adenosine, glucose-

277 lpha1 type I collagen and PDGFRbeta, produce erythropoietin through HIF2alpha regulation but that pro

278 raumatic administration of recombinant human erythropoietin, thus offering new perspectives in the us

279 hepcidin indirectly through the capacity of erythropoietin to stimulate erythropoiesis.

280 pha is thought to be the master regulator of erythropoietin transcription.

281 le factor-2alpha (HIF-2alpha) expression and erythropoietin transcription.

282 EGF, VEGF receptor 1 (VEGFR1), VEGFR2, Tie2, erythropoietin, transforming growth factor beta1, insuli

283 ed in increased heme levels, and hypoxia and erythropoietin treatment increased heme production throu

284 Erythropoietin treatment is neuroprotective in animal ex

285 clinical trial of preterm infants, high-dose erythropoietin treatment within 42 hours after birth was

286 ulation of mesenchymal progenitors, released erythropoietin under hypoxic conditions.

287 3) years and median (quartile 1, quartile 3) erythropoietin was 12.3 (9.0, 17.2) mIU/mL.

288 cident HF events, and each doubling of serum erythropoietin was associated with a 25% increased risk

289 iesis was shown by Leon Jacobson in 1957 and erythropoietin was eventually purified from the urine of

290 Serum erythropoietin was not significantly associated with the

291 Erythropoietin was shown to be neuroprotective in experi

292 lial cells (hRMVECs) stimulated with VEGF or erythropoietin were analyzed for p-STAT3.

293 pha, vascular endothelial growth factor, and erythropoietin were higher in term than preterm pups, re

294 CD133(+) progenitor cells stopped producing erythropoietin when they differentiated and acquired an

295 ions after the switch from recombinant human erythropoietin, whereas mean hemoglobin decreased in the

296 There was no interaction of serum erythropoietin with chronic kidney disease or anemia (P

297 describe the total synthesis of homogeneous erythropoietin with consensus carbohydrate domains incor

298 Associations of erythropoietin with incident HF, coronary heart disease,

299 lobin occurred with elevations in endogenous erythropoietin within the range usually observed in the

300 tudy used a factorial design to test whether erythropoietin would fail to improve favorable outcomes